Sexual Function and AndroFeme

top of page

AndroFeme┬«1 represnts a new era in Women's Health in New Zealand

AndroFeme®1
HSDD
Education Platform
AndroFeme®1- Women's Health
Medical Professionals Member Page
AndroFeme®1- Women's Health
Medical Professionals Member Page
FAQ
Contact

Sexual Function and AndroFeme®1

CONTACT

info@alchemyhealth.co.nz

Tel: 0508 252436

QUICK LINKS

AndroFeme®1
HSDD
Educational Platform
- AndroFeme®1- Women's Health
- Medical Professionals Member Page
FAQ
Contact

LEGAL

Terms & Conditions

Privacy Policy

AndroFeme® 1 is a non-funded prescription medicine containing 1% w/v testosterone (10mg testosterone per 1 mL). Normal doctors’ fees and a prescription charge will apply. AndroFeme® 1 is indicated for the treatment of hypoactive sexual desire dysfunction (HSDD) in postmenopausal women. AndroFeme® 1 has risks and benefits. Testosterone supplementation in women must be monitored closely, especially at onset of treatment. Ask your doctor if AndroFeme® 1 is right for you. Use only as directed. If symptoms continue or side effects develop, see your doctor, pharmacist or healthcare professional. For further information about AndroFeme® 1, see the Consumer Medicine Information (CMI) available at www.medsafe.govt.nz. AndroFeme®1 is a registered trademark of Lawley Pharmaceuticals. Alchemy Health NZ Ltd, Auckland. TAPS: NP23449

References: 1. Worsley R. J Sex Med 2017;14(5):675-686. 2. Fooladi E. Climacteric 2014;17:674-681 3. Simon JA. Climacteric 2018:5:415-427 4. AndroFeme® 1 Data Sheet 5.Goldstein I, Mayo Clin Proc 2017;92(1):114-128. 6. Islam R. Lancet Diab Endo 2019;7(10):754-766 7. Clayton AH, et al. The International Society for the Study of Women’s Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. Mayo Clin Proc 2018;93(4):467–87. 8. Skiba M. 2019 JCEM; 104(11):5382-5392.

4

AndroFeme®1
HSDD
Education Platform
- AndroFeme®1- Women's Health
- Medical Professionals Member Page
FAQ
Contact

bottom of page